Gastric cancer in Alaska Native people: A cancer health disparity

Table 2 Descriptive epidemiology of Alaska Native gastric cancer patients n (%)

	Overall	Female	Male
Patients	132	50 (37.9)	82 (62.1)
Mean age (yr)	59.8 ± 1.2	62.4 ± 2.0	58.2 ± 1.4
Histological type
Diffuse	75 (56.8)	29 (58.0)	46 (56.1)
Intestinal	51 (38.6)	16 (32.0)	35 (42.7)
NOS	6 (4.5)	5 (10.0)	1 (1.2)
Blood type
A+	55 (41.7)	23 (46.0)	32 (39.0)
AB+	8 (6.1)	3 (6.0)	5 (6.1)
B+	9 (6.8)	5 (10.0)	4 (4.9)
O+	30 (22.7)	10 (20.0)	20 (24.4)
Unknown	30 (22.7)	9 (18.0)	21 (25.6)
Histological appearance
Signet Ring	52 (39.4)	23 (46.0)	29 (35.4)
Adenocarcinoma	80 (59.8)	27 (54.0)	53 (64.6)
Linitis Plastica, AC	2 (2.5)	0 (0)	2 (3.8)
Mucinous, AC	2 (2.5)	0 (0)	2 (3.8)
Tubular, AC	1 (1.3)	0 (0)	1 (1.9)
Papillary	1 (1.3)	0 (0)	1 (1.9)
NOS, AC	75 (93.8)	27 (100)	46 (86.8)
Stage
I	28 (21.2)	8 (16.0)	20 (24.4)
II	24 (18.2)	6 (12.0)	18 (22.0)
III	14 (11.4)	4 (8.0)	10 (12.2)
IV	66 (50.0)	32 (64.0)	34 (41.5)
Grade
Well/moderately differentiated	35 (26.5)	9 (18.0)	26 (31.7)
Poorly differentiated	88 (66.7)	36 (72.0)	52 (63.4)
Unknown	9 (6.8)	5 (10.0)	4 (4.9)
Anatomic site
GE JX	12 (9.1)	5 (10.0)	7 (8.5)
Cardia	10 (7.6)	5 (10.0)	5 (6.1)
Fundus	12 (9.1)	6 (12.0)	6 (7.3)
Body	33 (25.0)	10 (20.0)	23 (28.0)
Antrum	18(13.6)	8 (16.0)	10 (12.2)
Pylorus	17 (12.9)	7 (14.0)	10 (12.2)
Overlap (multifocal)	27 (20.5)	9 (18.0)	18 (22.0)
Unspecified	3 (2.3)	0 (0)	3 (3.7)
Regions of Alaska
North	38 (28.8)	17 (34.0)	21 (25.6)
Interior	11 (8.3)	1 (2.0)	10 (12.2)
Southwest	40 (30.3)	15 (30.0)	25 (30.5)
Southcentral	40 (30.3)	17 (34.0)	23 (28.0)
Southeast	3 (2.3)	0 (0)	3 (3.7)
Treatment2
Chemotherapy only	40 (30.3)	12 (24.0)	28 (34.1)
Neoadjuvant	21 (15.9)	8 (16.0)	13 (15.9)
Adjuvant	12 (9.1)	4 (8.0)	8 (9.8)
Resection only	12 (9.1)	5 (10.0)	7 (8.5)
Neoadjuvant, resection, adjuvant	9 (6.8)	3 (6.0)	6 (7.3)
None	38 (28.8)	18 (36.0)	20 (24.4)
Metastasis site1
Omentum/peritoneium/diaphram	27 (41.5)	14 (43.8)	13 (38.2)
Liver	14 (21.5)	6 (18.8)	8 (23.5)
Lung	1 (1.5)	0 (0)	1 (2.9)
Bone	2 (3.1)	0 (0)	2 (5.9)
Ovary	6 (9.2)	6 (18.8)	0 (0)
Multiple Sites	15 (23.1)	6 (18.8)	10 (29.4)
Additional clinical and pathological variables
H. pylori	52 (41.3)	20 (41.7)	32 (41.0)
Chronic gastritis	101 (76.5)	38 (76.0)	63 (76.8)
GERD	51 (39.5)	18 (36.0)	33 (41.3)
Gastric ulcer	91 (68.9)	35 (70.0)	56 (68.3)
Tobacco	108 (81.8)	36 (72.0)	72 (87.8)
Family history GI cancer	38 (28.8)	16 (32.0)	21 (25.6)

¹Patients with stage 4 gastric cancer were used for analysis;

²Neoadjuvant and adjuvant treatments include chemotherapy and chemoradiation regimens based on NCCN guidelines. NOS: Not otherwise specified; AC: Adenocarcinoma; GE JX: Gastroesophageal junction; H. pylori: Helicobacter pylori; GERD: Gastroesophageal reflux disease; GC: Gastric cancer.